Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: A prospective randomised study

M. Colozza; G. Bisagni; A. M. Mosconi; S. Gori; C. Boni; R. Sabbatini; A. Frassoldati; R. Passalacqua; A. Rosa Bian; C. Rodinò; E. Rondini; R. Algeri; S. Di Sarra; V. De Angelis; G. Cocconi; M. Tonato

doi:10.1016/S0959-8049(02)00452-5

Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: A prospective randomised study

M. Colozza, G. Bisagni, A. M. Mosconi, S. Gori, C. Boni, R. Sabbatini, A. Frassoldati, R. Passalacqua, A. Rosa Bian, C. Rodinò, E. Rondini, R. Algeri, S. Di Sarra, V. De Angelis, G. Cocconi, M. Tonato

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Article › peer-review

Abstract

We compared a relatively short regimen of monochemotherapy with epirubicin versus polychemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as adjuvant treatment for stage I and II breast cancer patients. 348 patients with oestrogen receptor negative (ER-) node negative and ER- or ER+ node-positive with

Original language	English
Pages (from-to)	2279-2288
Number of pages	10
Journal	European Journal of Cancer
Volume	38
Issue number	17
DOIs	https://doi.org/10.1016/S0959-8049(02)00452-5
Publication status	Published - Nov 2002

Keywords

Adjuvant therapy
Breast cancer
CMF
Epirubicin
Randomised study

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/S0959-8049(02)00452-5

Fingerprint Dive into the research topics of 'Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: A prospective randomised study'. Together they form a unique fingerprint.

Cite this

Colozza, M., Bisagni, G., Mosconi, A. M., Gori, S., Boni, C., Sabbatini, R., Frassoldati, A., Passalacqua, R., Bian, A. R., Rodinò, C., Rondini, E., Algeri, R., Di Sarra, S., De Angelis, V., Cocconi, G., & Tonato, M. (2002). Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: A prospective randomised study. European Journal of Cancer, 38(17), 2279-2288. https://doi.org/10.1016/S0959-8049(02)00452-5

Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer : A prospective randomised study. / Colozza, M.; Bisagni, G.; Mosconi, A. M.; Gori, S.; Boni, C.; Sabbatini, R.; Frassoldati, A.; Passalacqua, R.; Bian, A. Rosa; Rodinò, C.; Rondini, E.; Algeri, R.; Di Sarra, S.; De Angelis, V.; Cocconi, G.; Tonato, M.

In: European Journal of Cancer, Vol. 38, No. 17, 11.2002, p. 2279-2288.

Research output: Contribution to journal › Article › peer-review

Colozza, M, Bisagni, G, Mosconi, AM, Gori, S, Boni, C, Sabbatini, R, Frassoldati, A, Passalacqua, R, Bian, AR, Rodinò, C, Rondini, E, Algeri, R, Di Sarra, S, De Angelis, V, Cocconi, G & Tonato, M 2002, 'Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: A prospective randomised study', European Journal of Cancer, vol. 38, no. 17, pp. 2279-2288. https://doi.org/10.1016/S0959-8049(02)00452-5

Colozza, M. ; Bisagni, G. ; Mosconi, A. M. ; Gori, S. ; Boni, C. ; Sabbatini, R. ; Frassoldati, A. ; Passalacqua, R. ; Bian, A. Rosa ; Rodinò, C. ; Rondini, E. ; Algeri, R. ; Di Sarra, S. ; De Angelis, V. ; Cocconi, G. ; Tonato, M. / Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer : A prospective randomised study. In: European Journal of Cancer. 2002 ; Vol. 38, No. 17. pp. 2279-2288.

@article{080a7286961d432a91b801674917ac49,

title = "Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: A prospective randomised study",

abstract = "We compared a relatively short regimen of monochemotherapy with epirubicin versus polychemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as adjuvant treatment for stage I and II breast cancer patients. 348 patients with oestrogen receptor negative (ER-) node negative and ER- or ER+ node-positive with ",

keywords = "Adjuvant therapy, Breast cancer, CMF, Epirubicin, Randomised study",

author = "M. Colozza and G. Bisagni and Mosconi, {A. M.} and S. Gori and C. Boni and R. Sabbatini and A. Frassoldati and R. Passalacqua and Bian, {A. Rosa} and C. Rodin{\`o} and E. Rondini and R. Algeri and {Di Sarra}, S. and {De Angelis}, V. and G. Cocconi and M. Tonato",

year = "2002",

month = nov,

doi = "10.1016/S0959-8049(02)00452-5",

language = "English",

volume = "38",

pages = "2279--2288",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "17",

}

TY - JOUR

T1 - Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer

T2 - A prospective randomised study

AU - Colozza, M.

AU - Bisagni, G.

AU - Mosconi, A. M.

AU - Gori, S.

AU - Boni, C.

AU - Sabbatini, R.

AU - Frassoldati, A.

AU - Passalacqua, R.

AU - Bian, A. Rosa

AU - Rodinò, C.

AU - Rondini, E.

AU - Algeri, R.

AU - Di Sarra, S.

AU - De Angelis, V.

AU - Cocconi, G.

AU - Tonato, M.

PY - 2002/11

Y1 - 2002/11

N2 - We compared a relatively short regimen of monochemotherapy with epirubicin versus polychemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as adjuvant treatment for stage I and II breast cancer patients. 348 patients with oestrogen receptor negative (ER-) node negative and ER- or ER+ node-positive with

AB - We compared a relatively short regimen of monochemotherapy with epirubicin versus polychemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as adjuvant treatment for stage I and II breast cancer patients. 348 patients with oestrogen receptor negative (ER-) node negative and ER- or ER+ node-positive with

KW - Adjuvant therapy

KW - Breast cancer

KW - CMF

KW - Epirubicin

KW - Randomised study

UR - http://www.scopus.com/inward/record.url?scp=0036850387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036850387&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(02)00452-5

DO - 10.1016/S0959-8049(02)00452-5

M3 - Article

C2 - 12441265

AN - SCOPUS:0036850387

VL - 38

SP - 2279

EP - 2288

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 17

ER -